Tag: mavacamten

23-HVI-4172009 CQD 650×450-2
August 29, 2023/Research

Updates From CLEAR Outcomes and VALOR-HCM: Expanded Benefits With Bempedoic Acid and Mavacamten

Additional analyses of the two trials presented at 2023 ESC Congress

22-HVI-3509429_obstructive-hypertrophic-cardiomyopathy_650x450
January 27, 2023/Clinical Cardiology

Advances in Hypertrophic Cardiomyopathy Therapy: VALOR-HCM May Be Just the Beginning

An abundance of promising studies are on the horizon

22-HVI-3393756_echo-showing-obstructive-HCM_ 650×450
December 2, 2022/Imaging

VALOR-HCM Substudy: Mavacamten Improves Left Ventricular Diastolic Function

Gains are associated with clinical and biomarker benefits in obstructive HCM

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

22-HVI-2769712_hyptertrophic-cardiomyopathy_650x450
April 5, 2022/Clinical Cardiology

Mavacamten Significantly Reduces Patients’ Need for Septal Reduction Therapy Over 16 Weeks

Longer-term confirmation of VALOR-HCM could yield a noninvasive therapy for severe obstructive HCM

cardiac magnetic resonance images showing hypertrophic cardiomyopathy
March 9, 2020/Research

Hypertrophic Cardiomyopathy: Signs of Progress Toward a Medical Therapy and Refined Risk Prediction

New and ongoing studies aim to reduce the need for surgery, improve risk stratification

BackPage 1 of 1Next
Advertisement
Ad